Immunothérapie dans les tumeurs MSI non colorectales (notice n° 665231)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 03122cam a2200313 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121193901.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | de la Fouchardière, Christelle |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Immunothérapie dans les tumeurs MSI non colorectales |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2023.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 70 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Non-colorectal MSI/dMMR (microsatellite instability/deficient MMR system) tumors are mostly represented by gastric and small bowel cancers. Nevertheless, their presence is ubiquitous, even if it is very rare in certain anatomical and histological locations. Their management has been revolutionized by the introduction of immune checkpoint inhibitors (ICI) (in particular anti-PD-1 and PD-L-1) which have shown interesting response rates, both in patients with advanced, metastatic disease, but also in a neoadjuvant setting with a localized tumor. Moreover, even if the treatment standards have not evolved in France concerning access to ICI partly due to the absence of randomized comparative study, the search for MSI/dMMR is recommended for any digestive tumor in localized or metastatic situation. In fact, the inclusion of patients in a clinical trial evaluating immunotherapy will be preferred over conventional chemotherapy treatment. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Les tumeurs MSI/dMMR (instabilité microsatellitaire/système MMR déficient) non colorectales sont représentées majoritairement par les cancers gastriques et de l’intestin grêle. Néanmoins, leur présence est ubiquitaire même si elle est très rare dans certaines localisations anatomiques et certains types histologiques. La prise en charge de ces cancers a été révolutionnée par les inhibiteurs des points de contrôle immunitaire (ICI) (en particulier anti-PD-1 et PD-L-1) qui ont montré des taux de réponse intéressants, à la fois chez des patients présentant une maladie avancée, métastatique, mais aussi en situation néo-adjuvante avec une tumeur localisée. Et même si les standards de traitement dans les tumeurs digestives MSI non colorectales n’ont pas évolué en France concernant l’accès aux ICI du fait de l’absence d’études comparatives randomisées, la recherche d’une instabilité microsatellitaire est recommandée pour toute tumeur digestive en situation localisée ou métastatique. En effet, l’inclusion des patients dans un essai clinique évaluant une immunothérapie sera privilégiée vis-à-vis d’un traitement classique de chimiothérapie. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | MSI/dMMR |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cancer des voies biliaires |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cancer du grêle |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cancer gastrique |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | immunothérapie |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cancer du pancréas |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | gastric cancer |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | MSI/dMMR |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | pancreatic cancer |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | biliary tract cancer |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | small-bowel cancer |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | immune checkpoint inhibitor |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Hépato-Gastro & Oncologie Digestive | 30 | N° Supp 4 | 2023-06-15 | p. 17-24 | 2115-3310 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-hepato-gastro-et-oncologie-digestive-2023-HS4-page-17?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-hepato-gastro-et-oncologie-digestive-2023-HS4-page-17?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux